FDA grants fast track designation to STRO-002 for advanced gynecologic cancers

The FDA granted fast track designation to STRO-002 for treatment of certain women with advanced gynecologic cancer.

The designation applies to use of the agent with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer who received one to three prior lines of systemic therapy.

Read more from Healio about FDA grants fast track designation to STRO-002 for advanced gynecologic cancers

JHVEPhoto/Shutterstock.com